Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aims: Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to investigate the efficacy and safety of anlotinib with and without immunotherapy in NSCLC.
Methods: Pathologically confirmed NSCLC patients (stage IIIB-IV) receiving anlotinib between November 2018 and February 2020 were enrolled for retrospective analysis. The outcomes and safety of overall patients were evaluated, and the efficacies of anlotinib plus immunotherapy and anlotinib alone was compared. The primary endpoint was progression-free survival (PFS).
Results: A total of 80 patients (median age: 62 years, range: 29-86 years) were included. Overall median PFS was 4.3 months (95% confidence interval (CI): 2.7-5.9 months). In univariate analysis, patients without mutation, previous EGFR target therapy, and brain metastasis had significantly longer PFS. Cox regression analysis showed that only brain metastasis was an independent predictor of PFS. The median PFS of patients receiving anlotinib plus immunotherapy was slightly longer than that of patients receiving anlotinib alone (4.2 3.1 months); however, the difference was not statistically significant. A tendency of longer median PFS was observed in patients with adenocarcinoma, wild type, stage IV, no liver metastasis, former smoker, ≥2 previous treatment lines, no previous VEGF or EGFR target therapies in anlotinib plus immunotherapy group. Treatments with anlotinib alone or anlotinib plus immunotherapy were well tolerable. The most common adverse events were fatigue, decreased hemoglobin count, hypertension, hand-foot syndrome, oral mucositis and hoarseness.
Conclusion: Anlotinib is well tolerable and effective in advanced NSCLC patients. Brain metastasis is an independent predictor of PFS in NSCLC patients receiving anlotinib. Future prospective studies with larger sample size and extended follow-up are needed to confirm the clinical benefit in NSCLC patients treated with anlotinib combined with immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358741 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.659380 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and Safety of Anlotinib-Related Therapeutic Regimens in Patients with Previously Immune Checkpoint Inhibitors-Treated Advanced NSCLC: A Real-World Exploratory Study.
Drug Des Devel Ther
September 2025
College of Pulmonary and Critical Care Medicine, the Eighth Medical Center of Chinese PLA General Hospital, Beijing, 100091, People's Republic of China.
Objective: This study aimed to identify the effectiveness and safety of anlotinib-related therapeutic regimens in patients with previously immune checkpoint inhibitors (ICIs)-treated advanced non-small cell lung cancer (NSCLC).
Methods: A total of 107 patients with previously ICIs-treated advanced NSCLC who received anlotinib-related regimens or single-agent chemotherapy in clinical practice were included in this study retrospectively. The anlotinib group (AG) included 54 patients who received anlotinib-related regimens, and the chemotherapy group (CG) consisted of 53 patients who received single-agent chemotherapy.
An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor.
Cancer Med
September 2025
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Background: Although immune checkpoint inhibitors (ICIs) have markedly improved first-line management of non-small cell lung cancer (NSCLC), many tumors eventually escape control after anti-PD-(L)1 therapy, leaving a clear therapeutic gap. Preclinical studies and preliminary clinical data suggest that coupling ICIs with anti-angiogenesis therapy can yield complementary antitumor effects. Consequently, we launched this investigation to evaluate the therapeutic benefit and tolerability of sintilimab, a PD-(L)1-blocking monoclonal antibody, together with the oral multi-target anti-angiogenesis agent anlotinib in metastatic NSCLC individuals experiencing progression after first-line PD-(L)1 inhibition.
View Article and Find Full Text PDFAnti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial.
Med
August 2025
Orthopaedic Oncology Services, Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China; Clinical Research Center of Motor System Disease of Zhejiang Province, Hangzhou 310009, China. Electronic address:
Background: There is no standard systemic therapy for unresectable chondrosarcoma. The purpose of this study is to explore the efficacy of combination therapy with an anti-PD-1 antibody and anlotinib in patients with advanced chondrosarcoma.
Methods: Patients with dedifferentiated or high-grade conventional chondrosarcoma were eligible.
Three-Year Follow-Up of the Phase II Trial for Resectable Non-Small-Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD-NeoFOUR Trial.
Thorac Cancer
August 2025
Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Background: Lung cancer is a leading cause of cancer-related deaths. Perioperative therapies, including neoadjuvant chemo-immunotherapy, have improved outcomes, but combining them with antiangiogenic drugs may offer further benefits. This study evaluated the 3-year efficacy and safety of neoadjuvant sintilimab, anlotinib, and chemotherapy in resectable NSCLC patients from the TD-NeoFOUR trial.
View Article and Find Full Text PDFBiomimetic anlotinib-loaded FePc-silicate nanoparticles for sonodynamic and immunotherapy in non-small cell lung cancer via dual PD-L1 modulation.
Colloids Surf B Biointerfaces
August 2025
Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130021, China; State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry, Jilin University, 2699 Qianjin Street, Changchun
Non-small cell lung cancer (NSCLC) accounts for approximately 85 % of all lung cancer cases, in urgent need for multimodal therapeutic strategies. Sonodynamic therapy (SDT) has recently emerged as a promising non-invasive strategy. Programmed death-ligand 1 (PD-L1) antibody represented immunotherapy has shown limited efficacy due to inadequate tumor accumulation and persistent intracellular PD-L1 signaling.
View Article and Find Full Text PDF